MindWalk (NASDAQ:HYFT) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

MindWalk (NASDAQ:HYFT) issued its earnings results on Wednesday. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01), FiscalAI reports. The business had revenue of $3.03 million for the quarter. MindWalk had a negative return on equity of 84.79% and a negative net margin of 89.65%.

MindWalk Price Performance

Shares of NASDAQ HYFT remained flat at $1.18 during mid-day trading on Friday. 75,225 shares of the stock were exchanged, compared to its average volume of 407,914. The business has a 50-day simple moving average of $1.55. The company has a quick ratio of 3.64, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $55.12 million, a PE ratio of -5.36 and a beta of 0.83. MindWalk has a 1-year low of $0.99 and a 1-year high of $3.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in MindWalk in the 4th quarter worth approximately $51,000. Bridgeway Capital Management LLC purchased a new position in shares of MindWalk during the 4th quarter valued at $91,000. Bank of Montreal Can increased its stake in shares of MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after acquiring an additional 24,500 shares during the last quarter. XTX Topco Ltd increased its stake in shares of MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after acquiring an additional 44,331 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of MindWalk by 147.3% during the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after acquiring an additional 96,018 shares in the last quarter. 6.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HYFT shares. JonesTrading initiated coverage on MindWalk in a research note on Thursday, April 16th. They set a “buy” rating and a $5.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of MindWalk in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $5.00.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.